Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual R&D Day on July 24, 2025.
- 07/17/2025
|
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. “Janeen's unique blend of corporate development, strategic execution, and cli.
- 05/15/2025
|
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates.
- 05/05/2025
|
Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout
- Janux Therapeutics' lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company's strong financial position, with $1.03 billion in cash, reduces near-term dilution risk and supports pipeline advancement without immediate capital needs. The recent stock pullback presents a buying opportunity, driven by profit-taking and broader market weakness, not negative company updates.
- 04/05/2025
|
Insiders Are Loading Up on These 4 Biotech Stocks Now
- Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
- 03/11/2025
|
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer.
- 01/24/2025
|
Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
- Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux's TRACTr and TRACIr platforms differentiate it in immunotherapy by enabling tumor-activated bispecific therapeutics for precise cancer targeting with minimal systemic toxicity. JANX's robust balance sheet, with $658.1 million in liquid assets and no debt. Oppenheimer identified Janux as a top biotech buyout candidate for 2025, citing its innovative platform and promising.
- 01/08/2025
|
Best-Performing Stocks Of 2024
- Best-Performing Stocks Of 2024
- 01/02/2025
|
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of.
- 12/06/2024
|
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purchas.
- 12/04/2024
|
Why Janux Therapeutics Crushed the Market Today
- News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (JANX 11.65%) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P 500 rising by 0.6%.
- 12/04/2024
|
JANX Stock Hits Record High on Prostate Cancer Study Data
- An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.
- 12/04/2024
|
Janux Therapeutics Announces Proposed Public Offering
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering.
- 12/03/2024
|
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
- On Monday, Janux Therapeutics, Inc. JANX revealed updated interim clinical data for its JANX007 clinical program.
- 12/03/2024
|
Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results
- The therapeutics company reports encouraging Phase 1 trial results for a novel cancer treatment.
- 12/03/2024
|
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC.
- 12/02/2024
|
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event.
- 11/25/2024
|
Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation
- Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong PSA reduction and favorable safety profile in phase 1 trials for metastatic castration-resistant prostate cancer. JANX007's innovative design addresses limitations of previous T cell engagers, showing potential for reduced toxicities and improved patient outcomes.
- 11/19/2024
|
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--3Q24 Earnings Release.
- 11/06/2024
|
Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?
- Janux Therapeutics (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 09/13/2024
|
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
- Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.42 per share a year ago.
- 08/07/2024
|
Janux Therapeutics Announces Updates to Board of Directors
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to its Board of Directors. “Eric and Natasha's vast experience and proven leadership in the biopharmaceutical indus.
- 07/22/2024
|
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
- Generally, the idea of selling securities rankles the public's nerve, yet trimming overbought stocks is just as important a discipline as knowing what to buy. It might be even more important than the latter concept.
- 04/17/2024
|
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
- Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.
- 04/16/2024
|
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
- Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.
- 04/15/2024
|
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 04/12/2024
|
Why Janux Therapeutics Stock Is Crushing It This Week
- Janux Therapeutics' stock jumped this week after a report stated the company was exploring a sale. The company hasn't publicly commented on whether it's involved in acquisition discussions.
- 04/12/2024
|
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
- The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 40.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 04/11/2024
|
Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
- Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safety balance. Amidst takeover speculation, Janux stock's valuation surged, yet I advise caution due to the speculative nature of acquisition outcomes.
- 04/11/2024
|
Why Janux Therapeutics Stock Soared as the Market Sagged Today
- According to a media report, among other potential moves, the biotech is considering putting itself up for sale. It has apparently received buyout offers from pharmaceutical companies.
- 04/10/2024
|
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)
- Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 04/08/2024
|
Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know
- Janux Therapeutics (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/28/2024
|
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade
- The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 03/22/2024
|
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)
- Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.
- 03/20/2024
|
2 Stocks That Have More Than Tripled This Year: Are They Buys?
- Viking Therapeutics and Janux Therapeutics are flying high on the back of positive data readouts. However, there is a long road ahead and plenty of potential risks for both of these mid-cap biotechs.
- 03/15/2024
|
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights.
- 03/08/2024
|
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
- Janux Therapeutics just reported some phenomenal early Phase 1 data. It still needs to confirm the value of its programs and platform.
- 03/02/2024
|
5 Stocks That More Than Doubled in February
- Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
- 03/01/2024
|
Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics, Inc. (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 03/01/2024
|
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants.
- 02/29/2024
|
Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
- Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032.
- 02/27/2024
|
Janux Therapeutics Announces Proposed Public Offering of Common Stock
- SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering of Common Stock.
- 02/27/2024
|
Why Is Janux Therapeutics (JANX) Stock Up 108% Today?
- Janux Therapeutics (NASDAQ: JANX ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company posted interim results from two studies. According to a press release from Janux Therapeutics, both JANX007 and JANX008 are showing encouraging efficacy and safety data in their clinical trials.
- 02/27/2024
|
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?
- Janux Therapeutics, Inc. (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 02/21/2024
|
Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 12/01/2023
|
Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High?
- The consensus price target hints at a 220.2% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/15/2023
|
Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- The heavy selling pressure might have exhausted for Janux Therapeutics, Inc. (JANX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 11/10/2023
|
Wall Street Analysts Think Janux Therapeutics, Inc. (JANX) Could Surge 120.82%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 120.8% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 08/10/2023
|
All You Need to Know About Janux Therapeutics, Inc. (JANX) Rating Upgrade to Buy
- Janux Therapeutics, Inc. (JANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 07/20/2023
|
Wall Street Analysts Believe Janux Therapeutics, Inc. (JANX) Could Rally 120.65%: Here's is How to Trade
- The consensus price target hints at a 120.7% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 07/20/2023
|
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates
- Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.32 per share a year ago.
- 05/09/2023
|
7 Biotech Stocks That Could Be the Next Big Thing
- While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.
- 03/15/2023
|
Janux Therapeutics, Inc. (JANX) Surges 5.9%: Is This an Indication of Further Gains?
- Janux Therapeutics, Inc. (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 02/14/2023
|
Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Janux Therapeutics, Inc. (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 01/10/2023
|
Janux Therapeutics to Present at Upcoming Investor Conferences in November
- SAN DIEGO--( BUSINESS WIRE )--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings. Details of the presentations are as follows:
- 11/22/2022
|
7 Short-Squeeze Stocks for Bold Contrarians to Consider
- Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's version of playing chicken.
- 11/21/2022
|
Why Janux Therapeutics Shares Rose 33.1% This Week
- The clinical-stage biotech company just began its first clinical trial.
- 10/22/2022
|
Janux Therapeutics to Present at Upcoming March Investor Conferences
- SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in three upcoming investor conferences: Cowen's 42nd Annual Health Care Conference Forum: Panel titled “Novel IO” Location: Virtual Date: Monday
- 03/01/2022
|
Week 7 MDA Breakout Stocks - February 2022: Short-Term Picks To Give You An Edge
- Week 7 MDA Breakout Stocks - February 2022: Short-Term Picks To Give You An Edge
- 02/13/2022
|
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
- SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13. The fireside chat will be available for on-
- 01/05/2022
|
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
- SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the virtual H.C. Wainwright 23rd Annual Global Investor Conference being held September 13 to 15, 2021. The corporate presentation will be availa
- 09/07/2021
|
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
- LA JOLLA, Calif.--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previously announced initial public offering of 13,110,000 shares of its common stock, which includes 1,710,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $17.00 per share. Including the option exercise, th
- 06/15/2021
|
Merck Partners With Newly Public Cancer Biotech
- The 37th biotech to hit the public markets this year has a potentially $1 billion deal with Merck & Co. Inc. ( MRK , Financial).
- 06/14/2021
|
U.S. IPO Weekly Recap: Summer's First Wave Brings 10 IPOs
- U.S. IPO Weekly Recap: Summer's First Wave Brings 10 IPOs
- 06/11/2021
|
Janux Therapeutics stock opens at double the upsized IPO's pricing
- Janux Therapeutics Inc. received a bullish reception on its Wall Street debut, as shares of the California-based biotechnology company developing cancer treatments opened at double the upsized initial public offering price before paring some gains. The company raised $193.8 million as it sold 11.4 million shares in the IPO, which priced at $17 a share.
- 06/11/2021
|
3 Stocks Make Their Trading Debuts Friday. What Investors Need to Know.
- The IPO market is ending the week with three deals. Kanzhun, a Chinese job-recruitment app; TaskUs, a digital outsourcer; and biotech Janux Therapeutics are listing their shares Friday.
- 06/11/2021
|
